Latest research on Sensipar

Cinacalcet (INN) is a drug that acts as a calcimimetic (i.e. it mimics the action of calcium on tissues) by allosteric activation of the calcium-sensing receptor that is expressed in various human organ tissues. It is sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. Cinacalcet is used to treat hyperparathyroidism (elevated parathyroid hormone levels), a consequence of parathyroid tumors and chronic renal failure.

Sensipar dosage

For Risperdal and Mimpara, the number of drug packages sold in 2010 was provided by the pharmaceutical manufacturer (IMS Health sales figures) and the number of actual users was calculated indirectly based on the usual dosage prescribed (19). [source, 2014]
Sixty-nine percent were already receiving low-dose oral Calcitriol (Rocaltrol, mainly given post-dialysis), 19% cinacalcet (Mimpara), and one patient intravenous Paricalcitol (Zemplar). [source, 2014]
According to the package insert for Sensipar (cinacalcet) (Amgen 2012), “serum calcium and serum phosphorus should be measured within 1 week and iPTH should be measured 1–4 weeks after initiation or dose adjustment of Sensipar®. [source, 2013]